当前期刊: Hypertension Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension
    Hypertension (IF 7.017) Pub Date : 2020-02-17
    Curt D. Sigmund; Robert M. Carey; Lawrence J. Appel; Donna K. Arnett; Hayden B. Bosworth; William C. Cushman; Zorina S. Galis; Melissa Green Parker; John E. Hall; David G. Harrison; Alicia A. McDonough; Holly L. Nicastro; Suzanne Oparil; John W. Osborn; Mohan K. Raizada; Jacqueline D. Wright; Young S. Oh

    The National Heart, Lung, and Blood Institute convened a multidisciplinary working group of hypertension researchers on December 6 to 7, 2018, in Bethesda, MD, to share current scientific knowledge in hypertension and to identify barriers to translation of basic into clinical science/trials and implementation of clinical science into clinical care of patients with hypertension. The goals of the working group were (1) to provide an overview of recent discoveries that may be ready for testing in preclinical and clinical studies; (2) to identify gaps in knowledge that impede translation; (3) to highlight the most promising scientific areas in which to pursue translation; (4) to identify key challenges and barriers for moving basic science discoveries into translation, clinical studies, and trials; and (5) to identify roadblocks for effective dissemination and implementation of basic and clinical science in real-world settings. The working group addressed issues that were responsive to many of the objectives of the National Heart, Lung, and Blood Institute Strategic Vision. The working group identified major barriers and opportunities for translating research to improved control of hypertension. This review summarizes the discussion and recommendations of the working group.

    更新日期:2020-02-18
  • Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia
    Hypertension (IF 7.017) Pub Date : 2020-02-17
    Holger Stepan; Martin Hund; Theresa Andraczek

    Placental dysfunction underlies a spectrum of perinatal pathologies, including preeclampsia and fetal growth restriction. Angiogenesis-related factors, including sFlt-1 (soluble fms-like tyrosine kinase 1) and PlGF (placental growth factor), play an important role in placental dysfunction; altered levels are detectable several weeks before onset of pregnancy complications. In vitro diagnostic tests for these biomarkers can improve early diagnosis and facilitate prediction of maternal and fetal outcomes. We assessed evidence for combining angiogenic biomarkers with other biomarkers or clinical parameters to predict maternal/fetal outcomes in pregnant women with placental dysfunction. Pooled information on placental perfusion (ultrasonography, mean arterial pressure), clinical characteristics, and biomarker levels (PlGF) can improve first-trimester prediction and preeclampsia diagnosis. Angiogenic factors (sFlt-1/PlGF ratio; PlGF alone) with or without clinical characteristics can facilitate second-/third-trimester prediction of early-onset and late-onset preeclampsia. A combination of increased sFlt-1/PlGF ratio and ultrasound can rule out early fetal growth restriction. The sFlt-1/PlGF ratio is also a reliable tool for discriminating between pregnancy-related hypertensive disorders, including superimposed preeclampsia and gestational hypertension. Analysis of angiogenic factors with or without uterine Doppler substantially improves sensitivity and specificity for predicting adverse outcomes and iatrogenic preterm delivery. We propose to extend the American College of Obstetricians and Gynecologists definition of preeclampsia in the future to include the combination of new-onset hypertension and new-onset of altered angiogenic factors (sFlt-1/PlGF ratio or PlGF alone). In summary, altered angiogenic biomarkers indicate placental dysfunction, and their implementation into clinical practice will help reduce the considerable burden of morbidity and mortality associated with adverse pregnancy outcomes as a consequence of angiogenic-placental syndrome.

    更新日期:2020-02-18
  • Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
    Hypertension (IF 7.017) Pub Date : 2020-02-17
    Pierre Verweij; Parisa Danaietash; Bruno Flamion; Joël Ménard; Marc Bellet

    This study examined the dose-response characteristics of aprocitentan, a dual endothelin A/endothelin B receptor antagonist, in patients with essential hypertension. In a randomized, double-blind, parallel study design, eligible patients with a sitting diastolic blood pressure (BP) of 90–109 mm Hg received aprocitentan 5, 10, 25, or 50 mg, placebo, or lisinopril 20 mg as a positive control once daily for 8 weeks. Multiple automated office BP readings were obtained with patients resting unattended (unattended automated office BP) at baseline, weeks 2, 4, and 8. Ambulatory BP was monitored for 24 hours at baseline and week 8. After a single-blind placebo run-in period, 490 eligible patients were randomized to the double-blind phase, with 409 patients completing 8 weeks of therapy per protocol. Aprocitentan 10, 25, and 50 mg decreased sitting systolic/diastolic unattended automated office BP from baseline to week 8 (placebo-corrected decreases: 7.05/4.93, 9.90/6.99, and 7.58/4.95 mm Hg, respectively, P≤0.014 versus placebo), compared with an unattended automated office BP reduction of 4.84/3.81 mm Hg with lisinopril 20 mg. For patients with valid ambulatory BP, aprocitentan 10, 25, and 50 mg significantly decreased placebo-corrected 24-hour BP by 3.99/4.04, 4.83/5.89, and 3.67/4.45 mm Hg, respectively. Incidence of adverse events was similar in the aprocitentan groups (22.0%–40.2%) and the placebo group (36.6%). Aprocitentan produced dose-dependent decreases in hemoglobin, hematocrit, albumin, and uric acid, an increase in estimated plasma volume, but no change in weight versus placebo. These findings support further investigation of aprocitentan at doses of 10 to 25 mg in hypertension.Registration—URL: https://www.clinicaltrials.gov; Unique identifier: NCT02603809.

    更新日期:2020-02-18
  • Skeletal Muscle Reflex–Induced Sympathetic Dysregulation and Sensitization of Muscle Afferents in Type 1 Diabetic Rats
    Hypertension (IF 7.017) Pub Date : 2020-02-17
    Rie Ishizawa; Han-Kyul Kim; Norio Hotta; Gary A. Iwamoto; Wanpen Vongpatanasin; Jere H. Mitchell; Scott A. Smith; Masaki Mizuno

    The blood pressure response to exercise is exaggerated in the type 1 diabetes mellitus (T1DM). An overactive exercise pressor reflex (EPR) contributes to the potentiated pressor response. However, the mechanism(s) underlying this abnormal EPR activity remains unclear. This study tested the hypothesis that the heightened blood pressure response to exercise in T1DM is mediated by EPR-induced sympathetic overactivity. Additionally, the study examined whether the single muscle afferents are sensitized by PKC (protein kinase C) activation in this disease. Sprague-Dawley rats were intraperitoneally administered either 50 mg/kg streptozotocin (T1DM) or saline (control). At 1 to 3 weeks after administration, renal sympathetic nerve activity and mean arterial pressure responses to activation of the EPR, mechanoreflex, and metaboreflex were measured in decerebrate animals. Action potential responses to mechanical and chemical stimulation were determined in group IV afferents with pPKCα (phosphorylated-PKCα) levels assessed in dorsal root ganglia. Compared with control, EPR (58±18 versus 96±33%; P<0.05), mechanoreflex (21±13 versus 51±20%; P<0.05), and metaboreflex (40±20 versus 88±39%; P<0.01) activation in T1DM rats evoked significant increases in renal sympathetic nerve activity as well as mean arterial pressure. The response of group IV afferents to mechanical (18±24 versus 61±45 spikes; P<0.01) and chemical (0.3±0.4 versus 1.6±0.8 Hz; P<0.01) stimuli were significantly greater in T1DM than control. T1DM rats showed markedly increased pPKCα levels in dorsal root ganglia compared with control. These data suggest that in T1DM, abnormally muscle reflex-evoked increases in sympathetic activity mediate exaggerations in blood pressure. Further, sensitization of muscle afferents, potentially via PKC activation, may contribute to this abnormal circulatory responsiveness.

    更新日期:2020-02-18
  • Renal Denervation in Asia
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Kazuomi Kario; Byeong-Keuk Kim; Jiro Aoki; Anthony Yiu-tung Wong; Ying-Hsiang Lee; Nattawut Wongpraparut; Quang Ngoc Nguyen; Wan Azman Wan Ahmad; Soo Teik Lim; Tiong Kiam Ong; Tzung-Dau Wang

    The Asia Renal Denervation Consortium consensus conference of Asian physicians actively performing renal denervation (RDN) was recently convened to share up-to-date information and regional perspectives, with the goal of consensus on RDN in Asia. First- and second-generation trials of RDN have demonstrated the efficacy and safety of this treatment modality for lowering blood pressure in patients with resistant hypertension. Considering the ethnic differences of the hypertension profile and demographics of cardiovascular disease demonstrated in the SYMPLICITY HTN (Renal Denervation in Patients With Uncontrolled Hypertension)-Japan study and Global SYMPLICITY registry data from Korea and Taiwan, RDN might be an effective hypertension management strategy in Asia. Patient preference for device-based therapy should be considered as part of a shared patient-physician decision process. A practical population for RDN treatment could consist of Asian patients with uncontrolled essential hypertension, including resistant hypertension. Opportunities to refine the procedure, expand the therapy to other sympathetically mediated diseases, and explore the specific effects on nocturnal and morning hypertension offer a promising future for RDN. Based on available evidence, RDN should not be considered a therapy of last resort but as an initial therapy option that may be applied alone or as a complementary therapy to antihypertensive medication.

    更新日期:2020-02-13
  • Interpretation of Population Health Metrics
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Jan A. Staessen; Lutgarde Thijs; Wen-Yi Yang; Cai-Guo Yu; Fang-Fei Wei; Harry A. Roels; Tim S. Nawrot; Zhen-Yu Zhang

    Our objective was to gain insight in the calculation and interpretation of population health metrics that inform disease prevention. Using as model environmental exposure to lead (ELE), a global pollutant, we assessed population health metrics derived from the Third National Health and Nutrition Examination Survey (1988 to 1994), the GBD (Global Burden of Disease Study 2010), and the Organization for Economic Co-operation and Development. In the National Health and Nutrition Examination Survey, the hazard ratio relating mortality over 19.3 years of follow-up to a blood lead increase at baseline from 1.0 to 6.7 µg/dL (10th–90th percentile interval) was 1.37 (95% CI, 1.17–1.60). The population-attributable fraction of blood lead was 18.0% (10.9%–26.1%). The number of preventable ELE-related deaths in the United States would be 412 000 per year (250 000–598 000). In GBD 2010, deaths and disability-adjusted life-years globally lost due to ELE were 0.67 million (0.58–0.78 million) and 0.56% (0.47%–0.66%), respectively. According to the 2017 Organization for Economic Co-operation and Development statistics, ELE-related welfare costs were $1 676 224 million worldwide. Extrapolations from the foregoing metrics assumed causality and reversibility of the association between mortality and blood lead, which at present-day ELE levels in developed nations is not established. Other issues limiting the interpretation of ELE-related population health metrics are the inflation of relative risk based on outdated blood lead levels, not differentiating relative from absolute risk, clustering of risk factors and exposures within individuals, residual confounding, and disregarding noncardiovascular disease and immigration in national ELE-associated welfare estimates. In conclusion, this review highlights the importance of critical thinking in translating population health metrics into cost-effective preventive strategies.

    更新日期:2020-02-13
  • In Utero Antihypertensive Medication Exposure and Neonatal Outcomes
    Hypertension (IF 7.017) Pub Date : 2019-12-30
    Catherine A. Fitton; Michael Fleming; Markus F.C. Steiner; Lorna Aucott; Jill P. Pell; Daniel F. Mackay; James S. Mclay

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Mass Spectrometry Imaging Establishes 2 Distinct Metabolic Phenotypes of Aldosterone-Producing Cell Clusters in Primary Aldosteronism
    Hypertension (IF 7.017) Pub Date : 2020-01-20
    Na Sun; Lucie S. Meyer; Annette Feuchtinger; Thomas Kunzke; Thomas Knösel; Martin Reincke; Axel Walch; Tracy Ann Williams

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Somatic CACNA1H Mutation As a Cause of Aldosterone-Producing Adenoma
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Kazutaka Nanba; Amy R. Blinder; Juilee Rege; Namita G. Hattangady; Tobias Else; Chia-Jen Liu; Scott A. Tomlins; Pankaj Vats; Chandan Kumar-Sinha; Thomas J. Giordano; William E. Rainey

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Screening Rates for Primary Aldosteronism in Resistant Hypertension
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Gilad Jaffe; Zachary Gray; Gomathi Krishnan; Margaret Stedman; Yuanchao Zheng; Jialin Han; Glenn M. Chertow; John T. Leppert; Vivek Bhalla

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Stephen P. Juraschek; Addison A. Taylor; Jackson T. Wright Jr; Gregory W Evans; Edgar R. Miller III; Timothy B. Plante; William C. Cushman; Tanya R. Gure; William E. Haley; Imran Moinuddin; John Nord; Suzanne Oparil; Carolyn Pedley; Christianne L. Roumie; Jeff Whittle; Alan Wiggers; Ciarán Finucane; Rose Anne Kenny; Lawrence J. Appel; Raymond R. Townsend; for the SPRINT Research Group

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Circ-calm4 Serves as an miR-337-3p Sponge to Regulate Myo10 (Myosin 10) and Promote Pulmonary Artery Smooth Muscle Proliferation
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Junting Zhang; Yiying Li; Jing Qi; Xiufeng Yu; Huanhuan Ren; Xijuan Zhao; Wei Xin; Siyu He; Xiaodong Zheng; Cui Ma; Lixin Zhang; Bingxiang Wu; Daling Zhu

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Oleic Acid Attenuates Ang II (Angiotensin II)-Induced Cardiac Remodeling by Inhibiting FGF23 (Fibroblast Growth Factor 23) Expression in Mice
    Hypertension (IF 7.017) Pub Date : 2020-01-13
    Tianlong Liu; Hongyan Wen; Hao Li; Haochen Xu; Ning Xiao; Rui Liu; Luonan Chen; Yingying Sun; Li Song; Congxia Bai; Jing Ge; Yinhui Zhang; Jingzhou Chen

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Level of Physical Activity, Left Ventricular Mass, Hypertension, and Prognosis
    Hypertension (IF 7.017) Pub Date : 2019-12-30
    Gowsini Joseph; Jacob Louis Marott; Tor Biering-Sørensen; Martin Nygård Johansen; Hans A. Saevereid; Gitte Nielsen; Peter Schnohr; Eva Prescott; Peter Søgaard; Rasmus Mogelvang

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Left Ventricular Mass and Incident Chronic Kidney Disease
    Hypertension (IF 7.017) Pub Date : 2020-01-13
    Rajiv Agarwal; Rebecca J. Song; Ramachandran S. Vasan; Vanessa Xanthakis

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Changes in Stroke Volume After Renal Denervation
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Philip Lurz; Karl-Patrik Kresoja; Karl-Philipp Rommel; Maximilian von Roeder; Christian Besler; Christian Lücke; Matthias Gutberlet; Roland E. Schmieder; Felix Mahfoud; Holger Thiele; Steffen Desch; Karl Fengler

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Urinary Albumin, Sodium, and Potassium and Cardiovascular Outcomes in the UK Biobank
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Daniela Zanetti; Helene Bergman; Stephen Burgess; Themistocles L. Assimes; Vivek Bhalla; Erik Ingelsson

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Effects of Sodium Reduction on Energy, Metabolism, Weight, Thirst, and Urine Volume
    Hypertension (IF 7.017) Pub Date : 2020-01-20
    Stephen P. Juraschek; Edgar R. Miller III; Alexander R. Chang; Cheryl A.M. Anderson; John E. Hall; Lawrence J. Appel

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Association of Blood Pressure With Outcomes in Acute Stroke Thrombectomy
    Hypertension (IF 7.017) Pub Date : 2020-01-13
    Konark Malhotra; Nitin Goyal; Aristeidis H. Katsanos; Angeliki Filippatou; Eva A. Mistry; Pooja Khatri; Mohammad Anadani; Alejandro M. Spiotta; Else Charlotte Sandset; Amrou Sarraj; Georgios Magoufis; Christos Krogias; Lars Tönges; Apostolos Safouris; Lucas Elijovich; Mayank Goyal; Adam Arthur; Andrei V. Alexandrov; Georgios Tsivgoulis

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Therapeutic Relevance of Elevated Blood Pressure After Ischemic Stroke in the Hypertensive Rats
    Hypertension (IF 7.017) Pub Date : 2020-01-20
    Pratik C. Thakkar; Ailsa L. McGregor; P. Alan Barber; Julian F.R. Paton; Carolyn J. Barrett; Fiona D. McBryde

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Fetal Oxygen and Glucose Consumption in Human Pregnancy Complicated by Fetal Growth Restriction
    Hypertension (IF 7.017) Pub Date : 2019-12-30
    Irene Cetin; Emanuela Taricco; Chiara Mandò; Tatjana Radaelli; Simona Boito; Anna Maria Nuzzo; Dino A. Giussani

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Angiogenic Marker Prognostic Models in Pregnant Women With Hypertension
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Helen Perry; Julia Binder; Erkan Kalafat; Stuart Jones; Basky Thilaganathan; Asma Khalil

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Unique microRNA Signals in Plasma Exosomes from Pregnancies Complicated by Preeclampsia
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Hui Li; Yingshi Ouyang; Elena Sadovsky; W. Tony Parks; Tianjiao Chu; Yoel Sadovsky

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Increased Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a Low-Risk Cohort
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Dan-dan Wu; Ling Gao; Ou Huang; Kamran Ullah; Meng-xi Guo; Ye Liu; Jian Zhang; Lei Chen; Jian-xia Fan; Jian-zhong Sheng; Xian-hua Lin; He-feng Huang

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism
    Hypertension (IF 7.017) Pub Date : 2020-01-13
    Luuk J.J. Scheres; Willem M. Lijfering; Norbert F.M. Groenewegen; Sanne Koole; Christianne J.M. de Groot; Saskia Middeldorp; Suzanne C. Cannegieter

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Maternal Cardiovascular Disease 3 Decades After Preterm Birth
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Nathalie Auger; Brian J. Potter; Siyi He; Jessica Healy-Profitós; Mireille E. Schnitzer; Gilles Paradis

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Increased Incidence but Lack of Association Between Cardiovascular Risk Factors in Adults Born Preterm
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Adrien Flahault; Katryn Paquette; Rafael Oliveira Fernandes; Jacques Delfrate; Anik Cloutier; Mélanie Henderson; Jean-Claude Lavoie; Benoît Mâsse; Anne Monique Nuyt; Thuy Mai Luu

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Conflicting Effects of Fetal Growth Restriction on Blood Pressure Between Human and Rat Offspring
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Judith Kooiman; Fieke Terstappen; Lilian van Wagensveld; Arie Franx; Kimberley E. Wever; Tessa J. Roseboom; Jaap A. Joles; Hendrik Gremmels; A. Titia Lely

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Diminished Blood Pressure Profiles in Children With Down Syndrome
    Hypertension (IF 7.017) Pub Date : 2020-01-13
    Jonathan D. Santoro; Sarah Lee; Michael Mlynash; Elizabeth W. Mayne; Michael S. Rafii; Brian G. Skotko

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Hemodynamic Patterns and Target Organ Damage in Adolescents With Ambulatory Prehypertension
    Hypertension (IF 7.017) Pub Date : 2019-12-30
    Łukasz Obrycki; Janusz Feber; Tadeusz Derezinski; Weronika Lewandowska; Zbigniew Kułaga; Mieczysław Litwin

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Morning Blood Pressure Surge and Cardiovascular Disease Events and All-Cause Mortality in Blacks
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    John N. Booth III; Byron C. Jaeger; Lei Huang; Marwah Abdalla; Mario Sims; Mark Butler; Paul Muntner; Daichi Shimbo

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Influence of Age on Upper Arm Cuff Blood Pressure Measurement
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Dean S. Picone; Martin G. Schultz; Petr Otahal; J. Andrew Black; Willem J. Bos; Chen-Huan Chen; Hao-Min Cheng; Antoine Cremer; Nathan Dwyer; Ricardo Fonseca; Alun D. Hughes; Hack-Lyoung Kim; Peter S. Lacy; Esben Laugesen; Nobuyuki Ohte; Stefano Omboni; Christian Ott; Telmo Pereira; Giacomo Pucci; Philip Roberts-Thomson; Niklas B. Rossen; Roland E. Schmieder; Daisuke Sueta; Kenji Takazawa; Jiguang Wang; Thomas Weber; Berend E. Westerhof; Bryan Williams; Hirotsugu Yamada; Eiichiro Yamamoto; James E. Sharman; for the Invasive Blood Pressure Consortium

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Wintertime Wood Smoke, Traffic Particle Pollution, and Preeclampsia
    Hypertension (IF 7.017) Pub Date : 2020-01-06
    Vanessa Assibey-Mensah; J. Christopher Glantz; Philip K. Hopke; Todd A. Jusko; Kelly Thevenet-Morrison; David Chalupa; David Q. Rich

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Comparative and Functional Genomic Resource for Mechanistic Studies of Human Blood Pressure–Associated Single Nucleotide Polymorphisms
    Hypertension (IF 7.017) Pub Date : 2020-01-06
    Manoj K. Mishra; Eugene Y. Liang; Aron M. Geurts; Paul W.L. Auer; Pengyuan Liu; Sridhar Rao; Andrew S. Greene; Mingyu Liang; Yong Liu

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • C-C Motif Chemokine Receptor 7 Exacerbates Hypertension Through Effects on T Lymphocyte Trafficking
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Yi Wen; Nathan P. Rudemiller; Jiandong Zhang; Xiaohan Lu; Jiafa Ren; Jamie R. Privratsky; Robert Griffiths; Junyi J. Zhang; Gianna E. Hammer; Steven D. Crowley

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Transfer and Vascular Effect of Endothelin Receptor Antagonists in the Human Placenta
    Hypertension (IF 7.017) Pub Date : 2019-12-30
    Emilie Hitzerd; Rugina I. Neuman; Michelle Broekhuizen; Sinno H.P. Simons; Sam Schoenmakers; Irwin K.M. Reiss; Birgit C.P. Koch; Anton H. van den Meiracker; Jorie Versmissen; Willy Visser; A.H. Jan Danser

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Smart Baroreceptor Activation Therapy Strikingly Attenuates Blood Pressure Variability in Hypertensive Rats With Impaired Baroreceptor
    Hypertension (IF 7.017) Pub Date : 2019-12-30
    Takeshi Tohyama; Kazuya Hosokawa; Keita Saku; Yasuhiro Oga; Hiroyuki Tsutsui; Kenji Sunagawa

    Download figure Download PowerPoint

    更新日期:2020-02-13
  • Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus
    Hypertension (IF 7.017) Pub Date : 2020-02-03
    Steven M. Smith; Almut G. Winterstein; Carl J. Pepine; Rhonda M. Cooper-DeHoff

    A recently published analysis in Hypertension suggests that thiazide use, versus nonuse, is associated with excess risk of adverse cardiovascular outcomes in patients with diabetes mellitus enrolled in the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). Here, we replicate these findings using the same publicly available datasets and following their reported methods. We further show that possible misclassification of thiazide exposure exists in the original analysis. We perform alternative analyses that correct for this misclassification to highlight the impact that misclassification can have on observed associations between an exposure (eg, thiazides) and outcomes (eg, stroke and major adverse cardiovascular events).

    更新日期:2020-02-13
  • Differential DNA Methylation in Placenta Associated With Maternal Blood Pressure During Pregnancy
    Hypertension (IF 7.017) Pub Date : 2020-02-10
    Tsegaselassie Workalemahu; Marion Ouidir; Deepika Shrestha; Jing Wu; Katherine L. Grantz; Fasil Tekola-Ayele

    Abnormal blood pressure during pregnancy is associated with impaired fetal growth, predisposing the offspring to cardiometabolic abnormalities over the life-course. Placental DNA methylation may be the regulatory pathway through which maternal blood pressure influences fetal and adult health outcomes. Epigenome-wide association study of 301 participants with placenta sample examined associations between DNA methylation and millimetre of mercury increases in systolic and diastolic blood pressure in each trimester. Findings were further examined using gene expression, gene pathway, and functional annotation analyses. Cytosine-(phosphate)-guanine (CpGs) known to be associated with cardiometabolic traits were evaluated. Increased maternal systolic and diastolic blood pressure were associated with methylation of 3 CpGs in the first, 6 CpGs in the second, and 15 CpGs in the third trimester at 5% false discovery rate (P values ranging from 6.6×10−15 to 2.3×10−7). Several CpGs were enriched in pathways including cardiovascular-metabolic development (P=1.0×10−45). Increased systolic and diastolic blood pressure were associated with increased CpG methylation and gene expression at COL12A1, a collagen family gene known for regulatory functions in the heart. Out of 304 previously reported CpGs known to be associated with cardiometabolic traits, 36 placental CpGs were associated with systolic and diastolic blood pressure in our data. The present study provides the first evidence for associations between placental DNA methylation and increased maternal blood pressure during pregnancy at genes implicated in cardiometabolic diseases. Identification of blood pressure-associated methylated sites in the placenta may provide clues to early origins of cardiometabolic dysfunction and inform guidelines for early prevention.Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00912132.

    更新日期:2020-02-10
  • B6.Rag1 Knockout Mice Generated at the Jackson Laboratory in 2009 Show a Robust Wild-Type Hypertensive Phenotype in Response to Ang II (Angiotensin II)
    Hypertension (IF 7.017) Pub Date : 2020-02-10
    Anika Seniuk; Jonas L. Thiele; Andra Stubbe; Philipp Oser; Alva Rosendahl; Marlies Bode; Catherine Meyer-Schwesinger; Ulrich O. Wenzel; Heimo Ehmke

    A key finding supporting a causal role of the immune system in the pathogenesis of hypertension is the observation that RAG1 knockout mice on a C57Bl/6J background (B6.Rag1−/−), which lack functional B and T cells, develop a much milder hypertensive response to Ang II (angiotensin II) than control C57Bl/6J mice. Here, we report that we never observed any Ang II resistance of B6.Rag1−/− mice purchased directly from the Jackson Laboratory as early as 2009. B6.Rag1−/− mice displayed nearly identical blood pressure increases monitored via radiotelemetry and hypertensive end-organ damage in response to different doses of Ang II and different levels of salt intake (0.02%, 0.3%, and 3% NaCl diet). Similarly, restoration of T-cell immunity by adoptive cell transfer did not affect the blood pressure response to Ang II in B6.Rag1−/− mice. Full development of the hypertension-resistant phenotype in B6.Rag1−/− mice appears to depend on the action of yet unidentified nongenetic modifiers in addition to the absence of functional T cells.

    更新日期:2020-02-10
  • Expression of Concern
    Hypertension (IF 7.017) Pub Date : 2020-02-05

    Expression of ConcernPlease see the following related articles: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.14508

    更新日期:2020-02-06
  • Prognostic Relevance of Short-Term Blood Pressure Variability
    Hypertension (IF 7.017) Pub Date : 2020-01-27
    Alejandro de la Sierra; José R. Banegas; Michael Bursztyn; Gianfranco Parati; George Stergiou; Aina Mateu; Ernest Vinyoles; Julián Segura; Manuel Gorostidi; Luis M. Ruilope

    The prognostic relevance of short-term blood pressure (BP) variability in hypertension is not clearly established. We aimed to evaluate the association of short-term BP variability, assessed through ambulatory BP monitoring, with total and cardiovascular mortality in a large cohort of patients with hypertension. We selected 63 910 subjects from the Spanish ABPM Registry from 2004 to 2014, with a median follow-up of 4.7 years. Systolic and diastolic BP SD from 24 hours, daytime, and nighttime, weighted SD (mean of daytime and nighttime SD weighted for period duration), average real variability (mean of differences between consecutive readings), variation independent of the mean, and BP variability ratio (ratio between systolic and diastolic 24-hour SD) were calculated through 24-hour ambulatory BP monitoring performed at baseline. Association with total and cardiovascular mortality (obtained through death certificates) were assessed by Cox regression models adjusted for clinical confounders and BP. Patients who died during follow-up had higher values of BP variability compared with those remaining alive. In fully adjusted models, daytime, nighttime, and weighted SD, systolic and diastolic, as well as diastolic average real variability, were all significantly associated with total and cardiovascular mortality. Hazard ratios for 1 SD increase ranged from 1.05 to 1.09 for total mortality and from 1.07 to 1.12 for cardiovascular mortality. A nighttime systolic SD ≥12 mm Hg was independently associated with total (hazard ratio: 1.13 [95% CI, 1.06–1.21]) and cardiovascular mortality (hazard ratio: 1.21 [95% CI, 1.09–1.36]). We conclude that short-term BP variability is independently associated with total and cardiovascular mortality in patients with hypertension.

    更新日期:2020-01-27
  • Potassium-Enriched Salt Substitutes as a Means to Lower Blood Pressure
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    Raquel C. Greer; Matti Marklund; Cheryl A.M. Anderson; Laura K. Cobb; Arlene T. Dalcin; Megan Henry; Lawrence J. Appel

    Use of salt substitutes containing potassium chloride is a potential strategy to reduce sodium intake, increase potassium intake, and thereby lower blood pressure and prevent the adverse consequences of high blood pressure. In this review, we describe the rationale for using potassium-enriched salt substitutes, summarize current evidence on the benefits and risks of potassium-enriched salt substitutes and discuss the implications of using potassium-enriched salt substitutes as a strategy to lower blood pressure. A benefit of salt substitutes that contain potassium chloride is the expected reduction in dietary sodium intake at the population level because of reformulation of manufactured foods or replacement of sodium chloride added to food during home cooking or at the dining table. There is empirical evidence that replacement of sodium chloride with potassium-enriched salt substitutes lowers systolic and diastolic blood pressure (average net Δ [95% CI] in mm Hg: –5.58 [–7.08 to –4.09] and –2.88 [–3.93 to –1.83], respectively). The risks of potassium-enriched salt substitutes include a possible increased risk of hyperkalemia and its principal adverse consequences: arrhythmias and sudden cardiac death, especially in people with conditions that impair potassium excretion such as chronic kidney disease. There is insufficient evidence regarding the effects of potassium-enriched salt substitutes on the occurrence of hyperkalemia. There is a need for additional empirical research on the effect of increasing dietary potassium and potassium-enriched salt substitutes on serum potassium levels and the risk of hyperkalemia, as well as for robust estimation of the population-wide impact of replacing sodium chloride with potassium-enriched salt substitutes.

    更新日期:2020-01-09
  • Nonalcoholic Fatty Liver Disease
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Yan-Ci Zhao; Guo-Jun Zhao; Ze Chen; Zhi-Gang She; Jingjing Cai; Hongliang Li

    Hypertension, a multifactorial disorder resulting from the interplay between genetic predisposition and environmental risk factors, affects ≈30% of adults. Emerging evidence has shown that nonalcoholic fatty liver disease (NAFLD), as an underestimated metabolic abnormality, is strongly associated with an increased risk of incident prehypertension and hypertension. However, the role of NAFLD in the development of hypertension is still obscure and is highly overlooked by the general public. Herein, we highlight the epidemiological evidence and putative mechanisms focusing on the emerging roles of NAFLD in hypertension, with the purpose of reinforcing the notion that NAFLD may serve as an independent risk factor and an important driving force in the development and progression of hypertension. Finally, we also briefly summarize the current potential treatments for NAFLD that might also be beneficial approaches against hypertension.

    更新日期:2020-01-09
  • High Blood Pressure and Cardiovascular Disease
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Flávio D. Fuchs; Paul K. Whelton

    Fragmented investigation has masked the overall picture for causes of cardiovascular disease (CVD). Among the risk factors for CVD, high blood pressure (BP) is associated with the strongest evidence for causation and it has a high prevalence of exposure. Biologically, normal levels of BP are considerably lower than what has typically been characterized as normal in research and clinical practice. We propose that CVD is primarily caused by a right-sided shift in the population distribution of BP. Our view that BP is the predominant risk factor for CVD is based on conceptual postulates that have been tested in observational investigations and clinical trials. Large cohort studies have demonstrated that high BP is an important risk factor for heart failure, atrial fibrillation, chronic kidney disease, heart valve diseases, aortic syndromes, and dementia, in addition to coronary heart disease and stroke. In multivariate modeling, the presumed attributable risk of high BP for stroke and coronary heart disease has increased steadily with progressive use of lower values for normal BP. Meta-analysis of BP-lowering randomized controlled trials has demonstrated a benefit which is almost identical to that predicted from BP risk relationships in cohort studies. Prevention of age-related increases in BP would, in large part, reduce the vascular consequences usually attributed to aging, and together with intensive treatment of established hypertension would eliminate a large proportion of the population burden of BP-related CVD.

    更新日期:2020-01-09
  • Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years
    Hypertension (IF 7.017) Pub Date : 2019-12-09
    Agostino Virdis; Stefano Masi; Edoardo Casiglia; Valerie Tikhonoff; Arrigo F.G. Cicero; Andrea Ungar; Giulia Rivasi; Massimo Salvetti; Carlo M. Barbagallo; Michele Bombelli; Raffaella Dell’Oro; Berardino Bruno; Luciano Lippa; Lanfranco D’Elia; Paolo Verdecchia; Francesca Mallamaci; Massimo Cirillo; Marcello Rattazzi; Pietro Cirillo; Loreto Gesualdo; Alberto Mazza; Cristina Giannattasio; Alessandro Maloberti; Massimo Volpe; Giuliano Tocci; Georgios Georgiopoulos; Guido Iaccarino; Pietro Nazzaro; Gianfranco Parati; Paolo Palatini; Ferruccio Galletti; Claudio Ferri; Giovambattista Desideri; Francesca Viazzi; Roberto Pontremoli; Maria Lorenza Muiesan; Guido Grassi; Claudio Borghi; from the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Blood Pressure Variability and Incidence of New-Onset Atrial Fibrillation
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    So-Ryoung Lee; You-Jung Choi; Eue-Keun Choi; Kyung-Do Han; Euijae Lee; Myung-Jin Cha; Seil Oh; Gregory Y.H. Lip

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Change in NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Level and Risk of Dementia in Multi-Ethnic Study of Atherosclerosis (MESA)
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Mohammad R. Ostovaneh; Kasra Moazzami; Kihei Yoneyama; Bharath A. Venkatesh; Susan R. Heckbert; Colin O. Wu; Steven Shea; Wendy S. Post; Annette L. Fitzpatrick; Gregory L. Burke; Hossein Bahrami; Otto A. Sanchez; Lori B. Daniels; Erin D. Michos; David A. Bluemke; João A.C. Lima

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Association of Extreme Nocturnal Dipping With Cardiovascular Events Strongly Depends on Age
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Paolo Palatini; Paolo Verdecchia; Lawrence J. Beilin; Kazuo Eguchi; Yutaka Imai; Kazuomi Kario; Takayoshi Ohkubo; Sante D. Pierdomenico; Francesca Saladini; Joseph E. Schwartz; Lindon Wing; Sara Signorotti; Gianpaolo Reboldi

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Blood Pressure Control and the Association With Diabetes Mellitus Incidence
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Christianne L. Roumie; Adriana M. Hung; Gregory B. Russell; Jan Basile; Kathryn Evans Kreider; John Nord; Thomas M. Ramsey; Anjay Rastogi; Mary Ellen Sweeney; Leonardo Tamariz; William J. Kostis; Jonathan S. Williams; Athena Zias; William C. Cushman; for the SPRINT Research Group

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Tiantian Zhang; Tengfei Lin; Yang Wang; Binyan Wang; Xianhui Qin; Feng Xie; Yimin Cui; Yong Huo; Xiaobin Wang; Zugui Zhang; Jie Jiang

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Ambient Airborne Particulates of Diameter ≤1 μm, a Leading Contributor to the Association Between Ambient Airborne Particulates of Diameter ≤2.5 μm and Children’s Blood Pressure
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    Qi-Zhen Wu; Shanshan Li; Bo-Yi Yang; Michael Bloom; Zhidong Shi; Luke Knibbs; Shyamali Dharmage; Ari Leskinen; Bin Jalaludin; Pasi Jalava; Marjut Roponen; Shao Lin; Gongbo Chen; Yuming Guo; Shu-Li Xu; Hong-Yao Yu; Mohammed Zeeshan; Li-Wen Hu; Yunjiang Yu; Xiao-Wen Zeng; Guang-Hui Dong

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Impact of Changes to National Hypertension Guidelines on Hypertension Management and Outcomes in the United Kingdom
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Sarah L. Lay-Flurrie; James P. Sheppard; Richard J. Stevens; Christian Mallen; Carl Heneghan; F.D. Richard Hobbs; Bryan Williams; Jonathan Mant; Richard J. McManus

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Influence of Genetic Variation in PDE3A on Endothelial Function and Stroke
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Matthew Traylor; Ali Amin Al Olama; Leo-Pekka Lyytikäinen; Sandro Marini; Jaeyoon Chung; Rainer Malik; Martin Dichgans; Mika Kähönen; Terho Lehtimäki; Christopher D. Anderson; Olli T. Raitakari; Hugh S. Markus

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Epigenetic Modifications in T Cells
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    John Henry Dasinger; Ammar J. Alsheikh; Justine M. Abais-Battad; Xiaoqing Pan; Daniel J. Fehrenbach; Hayley Lund; Michelle L. Roberts; Allen W. Cowley Jr; Srividya Kidambi; Theodore A. Kotchen; Pengyuan Liu; Mingyu Liang; David L. Mattson

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    Ewelina Józefczuk; Ryszard Nosalski; Blessy Saju; Eva Crespo; Piotr Szczepaniak; Tomasz Jan Guzik; Mateusz Siedlinski

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Gal-3 (Galectin-3) and KCa3.1 Mediate Heterogeneous Cell Coupling and Myocardial Fibrogenesis Driven by βAR (β-Adrenoceptor) Activation
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    Gang She; Meng-Chen Hou; Yu Zhang; Yi Zhang; Yan Wang; Hui-Fang Wang; Bao-Chang Lai; Wei-Bo Zhao; Xiao-Jun Du; Xiu-Ling Deng

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Aging Impairs Renal Autoregulation in Mice
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    Jin Wei; Jinxiu Zhu; Jie Zhang; Shan Jiang; Larry Qu; Lei Wang; Jacentha Buggs; Xuerui Tan; Feng Cheng; Ruisheng Liu

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Effects of Heterozygous TfR1 (Transferrin Receptor 1) Deletion in Pathogenesis of Renal Fibrosis in Mice
    Hypertension (IF 7.017) Pub Date : 2019-12-16
    Seiki Yasumura; Yoshiro Naito; Keisuke Okuno; Hisashi Sawada; Masanori Asakura; Tohru Masuyama; Masaharu Ishihara

    Download figure Download PowerPoint

    更新日期:2020-01-09
  • Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy
    Hypertension (IF 7.017) Pub Date : 2019-12-23
    Sjoerd A.M.E.G. Timmermans; Alexis Wérion; Jan G.M.C. Damoiseaux; Johann Morelle; Chris P. Reutelingsperger; Pieter van Paassen

    Download figure Download PowerPoint

    更新日期:2020-01-09
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
化学/材料学中国作者研究精选
Springer Nature 2019高下载量文章和章节
《科学报告》最新环境科学研究
ACS材料视界
自然科研论文编辑服务
中南大学国家杰青杨华明
剑桥大学-
中国科学院大学化学科学学院
材料化学和生物传感方向博士后招聘
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug